DCTH: delcath.com Price/Earnings to Growth Multiple
Delcath Systems, Inc. (DCTH) maintains high authority in liver therapy that promises growth, as confirmed by its PEG-based fair value assessment. Meanwhile, 3.65 determines the latest valuation metric. Development is based on eco-friendly chemotherapy methods and bioethics; however, alternative developments from corporate behemoths competing for clinical adoption create risk.
Analytical breakdowns for Delcath Systems, Inc. (DCTH)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
DCTH - Net Profit|Projected Future Earnings Delcath Systems, Inc.|DCTH - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Delcath Corp|DCTH - PEG Multiple|Business Value to Operating Income Before Depreciation Delcath|DCTH - Operating profit before deduction of amortization|Earnings per share for the trailing year Delcath Systems|DCTH - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months delcath.com|DCTH - Net earnings per share growth this year|Expected net earnings per share growth next year Delcath Systems, Inc.
General company analysis:DCTH - Delcath Systems Inc
The PEG ratio compares a stock's market value to its earnings growth rate, where a value below one signals that the asset is undervalued relative to its expansion. By analyzing the PEG ratio trend, an investor assesses price justification through the lens of the efficiency of the unique liver perfusion system from Delcath Systems, Inc. (DCTH), which provides the company with a long-term competitive advantage in specialized oncology.
Competitors of Delcath Systems, Inc.
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|PEG Multiple YMAB|aurabiosciences.com - Growth-Adjusted P/E Ratio|PEG Multiple CADL (Candel Therapeutics, Inc.)|Accuray Inc (ARAY) - Price to Earnings Adjusted for Growth Rate|SLS - Price/Earnings to Growth Ratio|ACTU: Price/Earnings to Growth Ratio|CTOR: PEG Multiple|Price/Earnings to Growth Multiple TuHURA Biosciences|TARA (Protara Therapeutics, Inc.) - PEG Multiple|PEG Multiple Fate Therapeutics Inc|Price/Earnings to Growth Multiple WHWK (Aadi Bioscience Inc)|Company Value to Earnings Growth Ratio TCRX|PEG Multiple CSBR (Champions Oncology, Inc.)|Growth-Adjusted Payback Ratio XBIT|CVM: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio OSTX (OS Therapies Inc.)|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ANL|Price to Earnings Adjusted for Growth Rate verupharma.com VERU|Price/Earnings to Growth Ratio Tempest Therapeutics, Inc. (TPST)|Growth-Adjusted Market Cap to Net Income xiliotx.com|Renovaro - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio MURA (Mural Oncology PLC)|Kairos Pharma Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Curis|Price/Earnings to Growth Ratio Apollomics Inc.|Tharimmune Corporation (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc)|GNPX (genprex.com) - Growth-Adjusted Payback Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|Growth-Adjusted Market Cap to Net Income Sunshine Biopharma Inc. (SBFM)|XBIO - Price/Earnings to Growth Ratio|SLRX (Salarius Pharma) - Growth-Adjusted P/E Ratio|PPBT: PEG Multiple|Price/Earnings to Growth Multiple American Oncology Network, Inc.|Price/Earnings to Growth Multiple BGNE|Checkpoint Therapeutics Inc. (CKPT) - Growth-Adjusted Market Cap to Net Income|PEG Multiple ELEV|icadmed.com - Growth-Adjusted P/E Ratio|PEG Multiple IKNA (Ikena Oncology)|NTBL - Price/Earnings to Growth Multiple|VIRX: Price/Earnings to Growth Multiple|MorphoSys Inc - Company Value to Earnings Growth Ratio|NAYA: PEG Multiple|Ascentage - Growth-Adjusted Payback Ratio
